Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking the access of arachidonic acid to the active site of the cyclooxygenases (COXs). Because the prostanoids produced by COX-1 appear to play a physiological role (protection of the gastric mucosa, platelet aggregation, vascular homeostasis, maintenance of renal sodium-water balance) while those produced by COX-2 seem mainly to intervene in the inflammatory response and in certain processes associated with cell proliferation, the hypothesis has been put forward that the NSAIDs that are selective COX-2 inhibitors should theoretically be capable of maintaining NSAID therapeutic properties but also have fewer adverse side effects due to the maintenance of prostaglandin production at normal physiological levels. Current knowledge and key points: The hypothesis of COX isoenzyme selectivity has led to a proposed classification for COX inhibitors: 1) COX-1 selective inhibitors (low-dosage aspirin); 2) COX non-selective inhibitors (the majority of classified NSAIDs, which when administered over the long term, e.g., in cases of rheumatoid arthritis, cause duodenal ulcers in 20% of cases and gastric hemorrhage in 1-4% of cases/year); 3) COX-2 preferential inhibitors (meloxicam and nimesulide, which have fewer gastric side effects than standard NSAIDs, but which are not risk-free at high doses); 4) COX-2 selective inhibitors (celecoxib and rofecoxib). Preliminary clinical studies have shown that COX-2 selective inhibitors are as efficient as standard NSAIDs and have fewer adverse digestive side effects, thereby confirming the interest of this proposed classification. In the UK, the aforementioned studies have led to the commercialization of rofecoxib for the treatment of pain and osteoarthritis, while celecoxib has been introduced in medical practice in the USA and other countries for the treatment of rheumatoid arthritis and osteoarthritis. Future prospects and projects: Various epidemiological and laboratory studies have indicated that NSAIDs may be able to reduce the risk of cancer (colorectal cancer in particular) and Alzheimer's disease due to their inhibitory activity on COXs, especially COX-2. The therapeutic contribution of COX-2 specific inhibitors has to be more fully evaluated, particularly as these agents could delay the healing of duodenal ulcers and interfere with several COX-2-induced physiological functions. It is therefore suggested that until further information becomes available, this new class of NSAIDs should be used with caution in certain patient populations.

Safety and rational choice of non-steroidal anti-inflammatory drugs

NSAIDs-induced gastrointestinal injury and its prevention

[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]

Cyclooxygenase-2 Inhibitors in Patients with High Gastrointestinal Risk: Are We There Yet?

Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration

Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

Management of the upper gastrointestinal adverse effect of non-steroid anti-inflammatory drugs

Safety profiles of leading nonsteroidal anti-inflammatory drugs

Primer: Managing NSAID-induced Ulcer Complications—balancing Gastrointestinal and Cardiovascular Risks

NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future

Advances in Selective COX-2 Inhibitors

Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives

Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Being on nonsteroidal anti-inflammatory drugs

Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient

Systematic Review with Network Meta-Analysis: Comparative Effectiveness and Safety of Strategies for Preventing NSAID-associated Gastrointestinal Toxicity

NSAID-induced gastrointestinal and cardiovascular injury.

Advances in Search for Adverse Reactions of Non-steroidal Anti-inflammatory Drugs

For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?

Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations